Jewish General Hospital (JGH) COVID-19 biobank, Canada

Registration Status: Pending

Objective: Research is essential to better understand the evolution and determinants of SARS-CoV-2 (COVID-19) infection, to identify those at risk and take the appropriate measures to protect them, to prioritize the resources of health care systems, to help the government take social measures to control the spread of infection and resumption of social activities, and to anticipate and better prepare for future pandemics. Access to high quality samples and data from witnesses and SARS-CoV-2 infected individuals who have given consent is absolutely essential. The urgency and scale of pandemics dictate immediate action and coordination of efforts at the local, regional, national and international levels. In the wake of the initiatives put forward to find a solution to the COVID-19 pandemic, the Fonds de recherche du QuÃ©bec - SantÃ© and GÃ©nome QuÃ©bec have mandated a group of researchers to set up the BQC19. The Public Health Agency of Canada (PHAC) joined the FRSQ and GC as a granting body for the BQC19 in June 2020. Jewish General Hospital has been one of initiative site of the BQC19 to collect bio-samples and data from COVID-19 tested patients led by Dr. Brent Richards. The mission of Jewish General Hospital COVID-19 biobank as part of the BQC19 is to ensure that scientists have access to the biological material and data necessary for their research efforts on COVID-19, to effectively respond to the public health challenges of the pandemic on solid scientific bases and within an appropriate ethical and legal framework.

Registered Biobank Name	Jewish General Hospital (JGH) COVID-19 biobank
Biobank Leader	Dr. Brent Richards
Country	Canada
Email for biobank inquiries	brent.richards@mcgill.ca
Principal Investigator	Dr. Brent Richards
Website
User Type Mono: A biobank that supports a specific research project, may have few staff members, a small-scale accrual scope with little to no initial intention of releasing or distributing biospecimens to secondary parties Oligo: A biobank that supports several research groups or clinical trials, may or may not be designed to release biospecimens outside their collaborative group Poly: A biobank that has generally a larger accrual scope, resources, and multiple users outside the biobank proper

Biospecimen Collected:

Cohort Highlights

100 cases Next Generation Sequencing assay to detect all classes of genetic variant in Lung Cancer using a single Diagnostic test.
200 cases Colorectal TMA for QC purposes in support of study of tumor infiltrating lymphocytes in ovarian cancer tissues.
Build 300 cases breast cancer TMA containing primary tumour and matched metastatic LN for various subtypes (luminal, HER2, Triple negative). Start with Triple negatives.
125 cases Breast tumour and metastatic lymph nodes in breast cancer cases with outcomes of metastasis to lung or bone.
100 cases of rare tumours - fibrolamellar hepatocellular carcinoma. FFPE, frozen, BC.
200 cases of FFPE tissue sections from breast, lung adenocarcinoma, and lung squamous cell carcinoma with matching normal tissue (only pathology data requested).